Objective Little is known about genetic contributors to higher than usual warfarin dose requirements, particularly for African Americans. This study tested the hypothesis that the γ-glutamyl carboxylase (GGCX) genotype contributes to warfarin dose requirements >7.5 mg/day in an African American population.
Introduction
Warfarin is the most widely prescribed oral agent for the prophylaxis of thromboembolic events. Subtherapeutic warfarin dosing increases the risk for thromboembolism, particularly during the initial months of therapy [1, 2] . Thus, obtaining therapeutic anticoagulation in a timely manner is a priority for clinicians managing warfarin.
Clinical factors are well known to influence the dose of warfarin required to produce therapeutic anticoagulation, with higher doses often necessary in those who are young, obese, taking medications that induce warfarin metabolism, or consuming large amounts of vitamin Kcontaining foods [3, 4] . More recently, the genotypes for cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex 1 (VKORC1) have been shown to affect warfarin pharmacokinetics and pharmacodynamics, respectively [5, 6] . The CYP2C9 enzyme metabolizes the more potent S-enantiomer of warfarin, while VKORC1 is the protein target of warfarin. Common CYP2C9 and VKORC1 variants have been associated with warfarin dose requirements across populations [7] [8] [9] [10] [11] [12] . In particular, the CYP2C9*2, CYP2C9*3, and VKORC1 -1639G>A variants were identified as major contributors to warfarin dose requirements within the usual range of 0.5 mg to 7.5 mg per day, especially in Caucasian and Asian populations [13] [14] [15] .
In 2010, the United States Food and Drug Administration approved revision of the warfarin labeling to include dosing recommendations based on the CYP2C9*2, CYP2C9*3, and VKORC1 -1639G>A variants, with recommended doses falling within the range of 0.5 to 7 mg/day [16] . Many patients require warfarin doses higher than 7 mg/day; yet, little is known about variants that contribute to higher than usual warfarin doses. This is particularly true in African Americans, who generally require higher doses than those of other racial groups. [4, 17] The gene encoding γ-glutamyl carboxylase (GGCX) is an additional candidate for influencing warfarin pharmacodynamics. The GGCX enzyme catalyzes the biosynthesis of vitamin K-dependent clotting factors by carboxylating protein-bound glutamate residues.
Warfarin exerts its anticoagulant effects by inhibiting the regeneration of a reduced form of vitamin K, which is essential for γ-carboxylation and activation of clotting factors II, VII, IX, and X. Rare GGCX mutations cause deficiencies in vitamin K-dependent clotting factors. [18] There are also data that more common GGCX variants influence warfarin dose variability in the general population [19] [20] [21] . Specifically, the rs699664 (p.R325Q) single nucleotide polymorphism (SNP) in exon 8, rs12714145 SNP in intron 2, and rs10654848 microsatellite in intron 6 have been associated with higher warfarin dose requirements in Caucasians and Asians [19] [20] [21] . We tested the hypothesis that the GGCX rs699664, rs12714145, and rs10654848 variants contribute to higher than usual warfarin dose requirements in African Americans. The GGCX rs11676382 SNP was recently associated with reduced warfarin dose requirements in European Caucasians [22] . However, it is reported to occur in less than 3% of African Americans, and thus was not included in our analysis [22, 23] .
Methods

African American population and procedures
The patient population and procedures have been previously described [9, 24] . Briefly, 338 African Americans ≥18 years of age, on stable warfarin therapy, defined as the same warfarin dose for ≥3 consecutive clinic visits, were recruited from the anticoagulation clinics at the University of Illinois Medical Center at Chicago (n=241) and the University of Chicago (n=97). Race was determined based on self-report, and none of the subjects reported mixed 5 ethnicity. One patient required a warfarin dose of 215 mg/week and was excluded from further analysis because such high dose requirements are often due to rare mutations associated with warfarin resistance rather than common variants associated with higher than usual doses in the general population [25] . After obtaining written informed consent, a buccal cell or whole blood sample was obtained for genetic analysis, and clinical data were collected. This study was approved by the Institutional Review Board at each location.
Genotyping
African Americans were genotyped for the CYP2C9 rs1799853 (p.R144C, *2), rs1057910 (p.I359L, *3), rs28371686 (p.D360E, *5), rs7900194 (p.R150H, *8), and rs28371685 (p.R335W, *11) alleles; VKORC1 rs9923231 (c.-1639G>A) variant, and recently described CYP2C9 rs7089580 and VKORC1 rs61162043 variants, using previously published methods. [24, 26, 27] . The GGCX rs12714145 (G>A) and rs699664 (p.R325Q) variants were determined by PCR and pyrosequencing, using published methods except with an annealing temperature of 58°C and primers shown in Table 1 [26, 27] . The GGCX rs10654848 (CAA)n genotype was determined by fragment analysis because of the difficulty with detecting heterozygous genotypes with sequencing. Thermocycling consisted of denaturation for 15 minutes at 95°C, followed by 40 cycles of denaturation at 95°C for 45 seconds, annealing at 55°C for 45 seconds, and extension at 72°C for 1 minute, with a final extension of 72°C for 10 minutes. The fragment analysis was performed using PCR product combined with GeneScan™ 1200 LIZ® Size Standard (Applied Biosystems, Life Technologies Corp, Carlsbad, CA) and Hi-Di™ Formamide (Applied Biosystems) on an ABI 3730x1 DNA Analyzer (Applied Biosystems). The results were analyzed using GeneMapper® v3.7 (Applied Biosystems). The number of GGCX CAA repeats was determined by capillary sequencing of at least one sample of each fragment size.
Because of their high minor allele frequencies (>0.40), the determination of the GGCX rs12714145 and rs699664 SNPs was restricted to African Americans enrolled from UIC. Given the large number of CAA repeats, with some having relatively low frequencies, we determined the GGCX (CAA) genotype in African Americans enrolled from both sites.
Swedish population
A total of 183 Swedish warfarin-treated patients were enrolled from Uppsala University Hospital anticoagulation clinic and genotyped for the GGCX rs10654848 (CAA)n repeat in order to compare frequencies of the CAA repeat between African Americans and European Caucasians. Patient characteristics, sample collection, and genotyping have been previously described [20, 28] .
Data analysis
Median weekly warfarin dose requirements were compared between GGCX genotype groups among African Americans by the Mann Whitney U test. Warfarin doses were initially compared among GGCX rs10654848 (CAA)n alleles to determine which alleles produced similar effects on dose and could be combined for comparisons between high and usual dose groups.
Clinical factors and genotype frequencies were then compared between African Americans requiring ≤7.5 mg/day (usual dose group) and >7. 
Results
The mean age of the African American population was 58 ± 16 years, and 71% were female. The mean warfarin dose was 6.4 ± 2.6 mg/day [median (range) 6.0 (1.6 to 15.7) mg/day]. Eighty-six (25%) patients required a warfarin dose >7.5 mg/day to maintain an INR within the target range.
Allele frequencies in the African American cohort are shown in Characteristics of African Americans requiring usual and high warfarin doses are shown in Table 4 . As expected, patients taking higher doses were younger and of larger body size. Of the genotypes tested, the VKORC1 -1639GG genotype, VKORC1 rs66162043 G allele, and GGCX (CAA)16/17 repeat were significantly overrepresented in the high dose group. The odds ratio for the association between the GGCX (CAA)16/17 repeat and dose requirements >7.5 mg/day was 4.0 (95% confidence interval 1.5-10.5). On logistic regression, age, body surface area (BSA), VKORC1 rs66162043 genotype, and GGCX (CAA)n genotype remained associated with doses >7.5 mg/day, while the association with the VKORC1 -1639GG genotype no longer reached statistical significance (Table 5 ).
For the linear regression model of genetic factors associated with log warfarin dose in African Americans, the GGCX (CAA)n genotype was the first variable entered in order to capture the variability explained by this variant alone (Table 6 ). The GGCX (CAA)n microsatellite explained 2% of the variability in warfarin dose in the study population (adjusted R 2 ). Next, we tested whether the GGCX (CAA)n genotype contributed to warfarin dose 
Discussion
Rare mutations in the VKORC1 gene have been associated with the warfarin resistance phenotype, where doses of 20 mg/day or higher are necessary to achieve therapeutic anticoagulation [32] . More recently, the ABCB1 3435C>T variant was associated with warfarin resistance in a Brazilian population [33] . In contrast, common VKORC1 as well as CYP2C9
SNPs correlate with the usual warfarin dose variability that occurs in the general population. In particular, the VKORC1 -1639G>A, CYP2C9*2 and CYP2C9*3 SNPs explain much of the variability (approximately 30% in Caucasians and 10% in African Americans) in warfarin dose within the range of 0.5 mg/day to 7.5 mg/day [8, 10, 11, 34] . African Americans generally require higher warfarin doses than those of other racial groups, and a significant portion of African Americans (25% in the current study) require doses >7.5 mg/day [10] . Lower frequencies of the CYP2C9*2, CYP2C9*3 and VKORC1 -1639A alleles among African
Americans compared to Caucasians contribute to the higher warfarin doses generally required in the former racial group [10] . In addition, the CYP2C9 rs7089580 and VKORC1 rs61162043 variants were recently found to occur frequently in African Americans and contribute to higher dose requirements in this population [24] . However, as demonstrated in the current study, the CYP2C9 and VKORC1 -1639A genotypes do not explain warfarin dose requirements above the usual dose range after accounting for other factors associated with high dose requirements. In the absence of mutations contributing to warfarin resistance, little is known about genetic contributors to higher than usual warfarin doses.
We found a significant association between the GGCX rs10654848 (CAA)n polymorphism and warfarin dose requirements >7.5 mg/day. In particular, 4 times as many patients requiring >7.5 mg/day of warfarin possessed a (CAA) 16 or 17 repeat compared to those requiring lower doses. While only 5% of our patients had a (CAA) 16 or 17 repeat, this was significantly higher than in the Swedish comparative cohort in our study. The higher prevalence of these alleles among African Americans may explain, in part, higher dose requirements observed in the African American population. The GGCX (CAA)n genotype was also associated with warfarin dose variability across our entire study population, but explained only a small portion of the total variability, likely because of its relatively low frequency.
While candidate gene studies in European Caucasian and Japanese patients have also implicated the GGCX (CAA)n repeat as a contributor to warfarin dose requirements, the data are inconsistent. Specifically, only the (CAA)10, 11, and 13 repeats were detected in an initial study in a Japanese population [29] . Three patients carried the (CAA)13 repeat and required significantly higher doses compared to those without this repeat. A more recent study revealed that the (CAA)8, 12, 14, and 15 (but not 16 or 17) repeats also occur in the Japanese population, but at low frequencies (<0.02) [31] . That study failed to replicate the previously observed association between the (CAA)13 repeat and warfarin dose. Dose requirements by the (CAA)n repeat were previously described in the Swedish population included in this study. Patients who were either homozygous for 13 repeats or carried at least one 14 to 16 repeat required higher dose requirements [20] . Another group of investigators also reported a correlation between number of CAA repeats and warfarin dose requirements; however, results were only significant in CYP2C9*1 allele homozygotes [35] . In the most recent study in Caucasians, only the (CAA)10, 11, 13, and 14 repeats were described [30] . In contrast to previous data, a higher number of repeats was associated with a lower warfarin dose in this population. None of the genome-wide association studies conducted to date identified the GGCX genotype as a major contributor to warfarin dose variability. [13] [14] [15] However, these studies were limited to Caucasian and Japanese patients, in whom the (CAA)16 and 17 repeats are rare to absent.
Neither the GGCX rs699664 nor rs12714145 variant was associated with higher warfarin dose requirements in our study. While the rs699664 SNP was correlated with warfarin dose in a Japanese population [19] , it was not associated with dose requirements in several different cohorts of European Caucasians [21, 30, [35] [36] [37] . Thus our negative finding with the rs699664 variant is consistent with the majority of previous data. Data with the rs12714145 variant have been inconsistent. However, in most studies, the rs12714145 SNP either explained only a small portion of the variability in warfarin dose or had no effect at all [21, 22, 30, 38] .
The mechanism by which the GGCX (CAA) repeat influences warfarin dose requirements has not been elucidated. Based on higher dose requirements with the 16 or 17
repeat, it seems plausible that higher repeats may enhance enzyme activity leading to greater carboxylation of clotting factors, which would presumably increase warfarin dose requirements.
However, this remains to be determined. Also, the inconsistencies in the data regarding the GGCX (CAA) repeat association with warfarin dose in other populations remain to be resolved, but could be secondary to near absence of the (CAA) 16 or 17 repeat in non-African populations.
In summary, we found that the GGCX rs10654848 (CAA) 16 or 17 repeat is significantly more common in African Americans compared to Caucasians and is associated warfarin dose requirements >7.5 mg/day. Current guidelines for anticoagulation management recommend warfarin starting doses of 5 mg/day for most patients, with lower doses in the elderly or those taking medications that reduce warfarin metabolism [3, 39] . The warfarin labeling suggests further dose adjustments based on the CYP2C9 and VKORC1 genotypes [16] . However, recommended doses fall within the range of 0.5 mg/day to 7 mg/day. Our data suggest that limiting starting doses within this range may result in under-dosing approximately 5% of African Americans who carry a (CAA) 16 or 17 repeat, thus potentially delaying their time to achieve therapeutic anticoagulation. Rather, our data suggest that, while the GGCX (CAA) repeat provides only a modest (2%) overall contribution to warfarin dose variability, it may be useful in identifying select African Americans who will require higher than usual doses. African
Americans are at particularly high risk for poor outcomes as a result of sub-therapeutic anticoagulation, with greater stroke-related disability and higher mortality rates from stroke and 13 pulmonary embolism compared to Caucasians [40] [41] [42] . Thus, achieving therapeutic anticoagulation efficiently is especially important for persons of African American race. 
